<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="letter-spacing: 0.1pt"><B>&nbsp;UNITED STATES<BR>
</B></FONT><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: 0.4pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: 0.4pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: 0.4pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: 0.4pt"><B>CURRENT
REPORT<BR>
</B></FONT><B><FONT STYLE="letter-spacing: -0.1pt">Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: -0.1pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: -0.1pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; font-size: 10pt"><FONT STYLE="letter-spacing: 0.1pt">Date of Report (Date of earliest event reported)</FONT></TD>
    <TD STYLE="width: 60%; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; font-size: 10pt; border-bottom: Black 1pt solid">February 10, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">NAVIDEA BIOPHARMACEUTICALS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<FONT STYLE="letter-spacing: -0.1pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: -0.1pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center; border-bottom: Black 1pt solid">Delaware</TD>
    <TD STYLE="width: 30%; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center; border-bottom: Black 1pt solid">0-26520</TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center; border-bottom: Black 1pt solid">31-1080091</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center">(State or other jurisdiction</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center">(Commission</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center">(IRS Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center">of incorporation)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center">File Number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center">Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41.4pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center; border-bottom: Black 1pt solid">425 Metro Place North, Suite 300, Columbus, Ohio</TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center; border-bottom: Black 1pt solid">43017</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: 0.05pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none"><FONT STYLE="letter-spacing: 0.1pt">Registrant's telephone number, including area code</FONT></TD>
    <TD STYLE="width: 57%; padding-right: 5.4pt; padding-left: 5.4pt; text-autospace: none; border-bottom: Black 1pt solid">(614) 793-7500</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: 0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: 0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: 0.1pt"><U></U></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: 0.1pt"><U></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: -0.15pt">(Former
name or former address, if changed since last report.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: -0.05pt">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant </FONT>under any of
the following provisions (see General Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT><FONT STYLE="letter-spacing: 0.1pt"> </FONT><FONT STYLE="letter-spacing: -0.05pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT> <FONT STYLE="letter-spacing: 0.1pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT> <FONT STYLE="letter-spacing: 0.1pt">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"><B>Item 5.02</B></TD><TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="text-align: justify"><B>Departure
                                                                                                of Directors or Certain Officers;
                                                                                                Election of Directors; Appointment
                                                                                                of Certain Officers; Compensatory
                                                                                                Arrangements of Certain Officers.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Awards Under 2011 Bonus Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In December 2010, the Compensation, Nominating
and Governance Committee (the &ldquo;Committee&rdquo;) of the Board of Directors of Navidea Biopharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
established the following corporate bonus objectives related to the Company&rsquo;s performance in 2011:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Achievement of specified 2011 annual revenue and gross margin goals for the Company&rsquo;s medical device and radiopharmaceutical
product lines, subject to 20% reduction of bonus if not achieved.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Completion of Phase 3 clinical activities for Lymphoseek<SUP>&reg;</SUP>, a proprietary radioactive lymphatic mapping targeting
agent being developed by the Company, and the successful filing of a new drug application (&ldquo;NDA&rdquo;) with the United States
Food and Drug Administration (the &quot;FDA&quot;) for Lymphoseek, subject to 40% reduction of bonus if not achieved.</TD></TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top"><TD></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The successful development and implementation of a clinical development plan and strategy for a product utilizing the Company's
RIGS<SUP>&reg;</SUP> technology, with either the FDA or the European Medicines Agency (&ldquo;EMA&rdquo;), the centralized regulatory
agency for the European Union, subject to 30% reduction of bonus if not achieved.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Discretionary bonus, equal to 10% of the total bonus objective.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In reviewing the previously established
goals for 2011, the Committee determined that the Company&rsquo;s mission, strategy and objectives changed significantly
since the time when the original corporate objectives and individual bonus targets were established, and a number of
significant positive accomplishments were achieved by the Company during the year that were not contemplated in establishing
2011 goals. With respect to the first objective, the sale of the Company&rsquo;s GDS line of gamma detection device systems
(the &ldquo;GDS Business&rdquo;) affected the Company&rsquo;s ability to meet the pre-specified goal relating to revenue.
However, as a result of the pro-rata achievement of the revenue goal through the point of the sale, coupled with the benefits
to the Company&rsquo;s financial position of the sale itself, the Committee considered that goal fully achieved. With regard
to the second objective, the Committee concluded that the filing and subsequent acceptance of the NDA evidenced the
successful achievement of that objective. In reviewing the third and fourth objectives, the Committee concluded that while
progress had been made on the RIGS technology through gaining regulatory feedback on RIGS from both the FDA and EMA and the
activities associated with the transition to a humanized RIGS antibody, that the number of unanticipated incremental
accomplishments which management and the staff of the Company had achieved should be recognized in assessing bonuses related
to 2011 performance. Representative of these incremental accomplishments were the listing on a major national stock exchange,
the sale of the GDS Business itself, the in-licensing of the AZD4694 Alzheimer&rsquo;s PET agent from AstraZeneca, the
closing of a $7M debt transaction, and overall appreciation of the stock price for the year. The Committee
therefore determined, at its discretion, that the 30% portion of the bonus attributable to the RIGS objective should be
combined with the original 10% discretionary objective to create an overall 40% discretionary portion of the overall bonus
objectives. With respect to the 40% discretionary portion, the progress on RIGS, as well as the recognition of the
incremental accomplishments described above, were evaluated in assessing the Company&rsquo;s overall successes for the year.
Based on the Committee&rsquo;s assessment of this revised discretionary objective, coupled with their evaluation of the
totality of the Company&rsquo;s achievements and individual&rsquo;s contributions in 2011, on February 10, 2012, the
Committee revised certain individual bonus targets and awarded bonuses in the following amounts to the Company&rsquo;s named
executive officers, such bonuses to be paid by March 15, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border: windowtext 1pt solid; padding: 3.75; font-weight: bold; text-decoration: underline; text-align: center; vertical-align: bottom">Officer</TD>
    <TD STYLE="width: 60%; border: windowtext 1pt solid; font-weight: bold; text-decoration: underline; text-align: center; vertical-align: bottom">Position</TD>
    <TD STYLE="width: 20%; border: windowtext 1pt solid; font-weight: bold; text-decoration: underline; text-align: center; vertical-align: bottom">Total 2011 Bonus Awarded</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: 3.75">Mark J. Pykett</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-indent: 3.75">President and Chief Executive Officer</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-align: center">$175,867</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: 3.75">Thomas H. Tulip</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-indent: 3.75">Executive Vice President and Chief Business Officer</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-align: center">$60,023</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: 3.75">Frederick O. Cope</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-indent: 3.75">Senior Vice President, Pharmaceutical Research and Clinical Development</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">$63,375</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: 3.75">Brent L. Larson</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-indent: 3.75">Senior Vice President and Chief Financial Officer</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-align: center">$43,875</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-indent: 3.75">Rodger A. Brown</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; text-indent: 3.75">Vice President, Regulatory Affairs and Quality Assurance</TD>
    <TD STYLE="border-right: windowtext 1pt solid; border-bottom: windowtext 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;$29,250</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1in 0 0; text-align: justify; text-indent: 0.25in">The Private Securities
Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company.
Statements contained or incorporated by reference in this Current Report on Form 8-K, which relate to other than strictly historical
facts, such as statements about the Company&rsquo;s plans and strategies, expectations for future financial performance, new and
existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company&rsquo;s products
are forward-looking statements within the meaning of the Act. The words &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;project,&rdquo; and similar expressions identify forward-looking statements that speak only as of
the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to
differ materially from historical or anticipated results due to many factors including, but not limited to, the Company&rsquo;s
continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition,
limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed
in the Company&rsquo;s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings. The Company
undertakes no obligation to publicly update or revise any forward-looking statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center"><FONT STYLE="letter-spacing: 0.1pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="letter-spacing: 0.2pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="letter-spacing: -0.15pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: justify"><FONT STYLE="letter-spacing: -0.15pt">&nbsp;</FONT></P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-autospace: none">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-autospace: none">&nbsp;Navidea Biopharmaceuticals, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-autospace: none">&nbsp;</TD>
    <TD STYLE="width: 2%; text-autospace: none">&nbsp;</TD>
    <TD STYLE="text-autospace: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-autospace: none">&nbsp;</TD>
    <TD STYLE="text-autospace: none">&nbsp;</TD>
    <TD STYLE="text-autospace: none">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -3.75pt; text-autospace: none">Date: February 16, 2012</TD>
    <TD STYLE="text-autospace: none">By:</TD>
    <TD STYLE="text-autospace: none; text-decoration: none; border-bottom: Black 1pt solid">/s/ Brent L. Larson</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-autospace: none">&nbsp;</TD>
    <TD STYLE="text-autospace: none">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Brent L. Larson, Senior Vice President and Chief Financial
Officer</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 10pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: justify"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v303040_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 25297}]
{"company-data": {"conformed-name": "NAVIDEA BIOPHARMACEUTICALS, INC.", "cik": "0000810509", "assigned-sic": "2835", "irs-number": "311080091", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35076", "film-number": "12620015"}, "business-address": {"street1": "425 METRO PLACE NORTH", "street2": "SUITE 300", "city": "DUBLIN", "state": "OH", "zip": "43017", "phone": "6147937500"}, "mail-address": {"street1": "425 METRO PLACE NORTH", "street2": "SUITE 300", "city": "DUBLIN", "state": "OH", "zip": "43017"}, "former-company": {"former-conformed-name": "NEOPROBE CORP", "date-changed": "19940714"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
February 10, 2012
NAVIDEA BIOPHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
0-26520
31-1080091
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
425 Metro Place North, Suite 300, Columbus, Ohio
43017
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code
(614) 793-7500
(Former
name or former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of
the following provisions (see General Instruction A.2. below):
£
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure
                                                                                                of Directors or Certain Officers;
                                                                                                Election of Directors; Appointment
                                                                                                of Certain Officers; Compensatory
                                                                                                Arrangements of Certain Officers.
Awards Under 2011 Bonus Plan
In December 2010, the Compensation, Nominating
and Governance Committee (the "Committee") of the Board of Directors of Navidea Biopharmaceuticals, Inc. (the "Company")
established the following corporate bonus objectives related to the Company's performance in 2011:
·
Achievement of specified 2011 annual revenue and gross margin goals for the Company's medical device and radiopharmaceutical
product lines, subject to 20% reduction of bonus if not achieved.
·
Completion of Phase 3 clinical activities for Lymphoseek
®
, a proprietary radioactive lymphatic mapping targeting
agent being developed by the Company, and the successful filing of a new drug application ("NDA") with the United States
Food and Drug Administration (the "FDA") for Lymphoseek, subject to 40% reduction of bonus if not achieved.
·
The successful development and implementation of a clinical development plan and strategy for a product utilizing the Company's
RIGS
®
technology, with either the FDA or the European Medicines Agency ("EMA"), the centralized regulatory
agency for the European Union, subject to 30% reduction of bonus if not achieved.
·
Discretionary bonus, equal to 10% of the total bonus objective.
In reviewing the previously established
goals for 2011, the Committee determined that the Company's mission, strategy and objectives changed significantly
since the time when the original corporate objectives and individual bonus targets were established, and a number of
significant positive accomplishments were achieved by the Company during the year that were not contemplated in establishing
2011 goals. With respect to the first objective, the sale of the Company's GDS line of gamma detection device systems
(the "GDS Business") affected the Company's ability to meet the pre-specified goal relating to revenue.
However, as a result of the pro-rata achievement of the revenue goal through the point of the sale, coupled with the benefits
to the Company's financial position of the sale itself, the Committee considered that goal fully achieved. With regard
to the second objective, the Committee concluded that the filing and subsequent acceptance of the NDA evidenced the
successful achievement of that objective. In reviewing the third and fourth objectives, the Committee concluded that while
progress had been made on the RIGS technology through gaining regulatory feedback on RIGS from both the FDA and EMA and the
activities associated with the transition to a humanized RIGS antibody, that the number of unanticipated incremental
accomplishments which management and the staff of the Company had achieved should be recognized in assessing bonuses related
to 2011 performance. Representative of these incremental accomplishments were the listing on a major national stock exchange,
the sale of the GDS Business itself, the in-licensing of the AZD4694 Alzheimer's PET agent from AstraZeneca, the
closing of a $7M debt transaction, and overall appreciation of the stock price for the year. The Committee
therefore determined, at its discretion, that the 30% portion of the bonus attributable to the RIGS objective should be
combined with the original 10% discretionary objective to create an overall 40% discretionary portion of the overall bonus
objectives. With respect to the 40% discretionary portion, the progress on RIGS, as well as the recognition of the
incremental accomplishments described above, were evaluated in assessing the Company's overall successes for the year.
Based on the Committee's assessment of this revised discretionary objective, coupled with their evaluation of the
totality of the Company's achievements and individual's contributions in 2011, on February 10, 2012, the
Committee revised certain individual bonus targets and awarded bonuses in the following amounts to the Company's named
executive officers, such bonuses to be paid by March 15, 2012:
Officer
Position
Total 2011 Bonus Awarded
Mark J. Pykett
President and Chief Executive Officer
$175,867
Thomas H. Tulip
Executive Vice President and Chief Business Officer
$60,023
Frederick O. Cope
Senior Vice President, Pharmaceutical Research and Clinical Development
$63,375
Brent L. Larson
Senior Vice President and Chief Financial Officer
$43,875
Rodger A. Brown
Vice President, Regulatory Affairs and Quality Assurance
$29,250
The Private Securities
Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company.
Statements contained or incorporated by reference in this Current Report on Form 8-K, which relate to other than strictly historical
facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and
existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products
are forward-looking statements within the meaning of the Act. The words "believe," "expect," "anticipate,"
"estimate," "project," and similar expressions identify forward-looking statements that speak only as of
the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to
differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's
continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated
deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition,
limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed
in the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other SEC filings. The Company
undertakes no obligation to publicly update or revise any forward-looking statements.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Navidea Biopharmaceuticals, Inc.
Date: February 16, 2012
By:
/s/ Brent L. Larson
Brent L. Larson, Senior Vice President and Chief Financial
Officer
3